Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Davine Hofste op Bruinink; S Oliva; L Rihova; A Schmitz; M Gilestro; Jeroen te Marvelde; R Kralova; H Høholt; A. Broijl; HE Johnsen; R Hajek; M Boccadoro; Pieter Sonneveld; P Omedè; Vincent van der Velden

doi:10.3324/haematol.2020.267831

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Davine Hofste op Bruinink, S Oliva, L Rihova, A Schmitz, M Gilestro, Jeroen te Marvelde, R Kralova, H Høholt, A. Broijl, HE Johnsen, R Hajek, M Boccadoro, Pieter Sonneveld, P Omedè, Vincent van der Velden

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

Original language	English
Journal	Haematologica
Volume	Online ahe
DOIs	https://doi.org/10.3324/haematol.2020.267831
Publication status	Published - 2020

Research programs

EMC MM-02-72-02
EMC OR-01

Access to Document

10.3324/haematol.2020.267831

Cite this

Hofste op Bruinink, D., Oliva, S., Rihova, L., Schmitz, A., Gilestro, M., te Marvelde, J., Kralova, R., Høholt, H., Broijl, A., Johnsen, HE., Hajek, R., Boccadoro, M., Sonneveld, P., Omedè, P., & van der Velden, V. (2020). Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network. Haematologica, Online ahe. https://doi.org/10.3324/haematol.2020.267831

@article{73a6fe0463884d9dae1dfcac9969c587,

title = "Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network",

author = "{Hofste op Bruinink}, Davine and S Oliva and L Rihova and A Schmitz and M Gilestro and {te Marvelde}, Jeroen and R Kralova and H H{\o}holt and A. Broijl and HE Johnsen and R Hajek and M Boccadoro and Pieter Sonneveld and P Omed{\`e} and {van der Velden}, Vincent",

year = "2020",

doi = "10.3324/haematol.2020.267831",

language = "English",

volume = "Online ahe",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Hofste op Bruinink, D, Oliva, S, Rihova, L, Schmitz, A, Gilestro, M, te Marvelde, J, Kralova, R, Høholt, H, Broijl, A, Johnsen, HE, Hajek, R, Boccadoro, M, Sonneveld, P, Omedè, P & van der Velden, V 2020, 'Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network', Haematologica, vol. Online ahe. https://doi.org/10.3324/haematol.2020.267831

TY - JOUR

T1 - Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

AU - Hofste op Bruinink, Davine

AU - Oliva, S

AU - Rihova, L

AU - Schmitz, A

AU - Gilestro, M

AU - te Marvelde, Jeroen

AU - Kralova, R

AU - Høholt, H

AU - Broijl, A.

AU - Johnsen, HE

AU - Hajek, R

AU - Boccadoro, M

AU - Sonneveld, Pieter

AU - Omedè, P

AU - van der Velden, Vincent

PY - 2020

Y1 - 2020

U2 - 10.3324/haematol.2020.267831

DO - 10.3324/haematol.2020.267831

M3 - Article

C2 - 33054135

SN - 0390-6078

VL - Online ahe

JO - Haematologica

JF - Haematologica

ER -